cc-97489
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 13, 2020 (NCT05099822)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Anandamide amidohydrolaseINHIBITOR
FAAH inhibitor
- Monoglyceride lipaseINHIBITOR
MGLL inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06227975 | Phase 1 | Feb 2, 2024 | Bristol-Myers Squibb, Celgene |
| NCT05065541 | Phase 1 | Sep 24, 2021 | Bristol-Myers Squibb, Celgene |
| NCT05099822 | Phase 1 | Mar 13, 2020 | Bristol-Myers Squibb, Celgene |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 3 | 0 | 1 | 2020 |
| Celgene | For profit | 3 | 3 | 1 | 2020 |
2 organizations
Page 1 / 1